Abstract
Abstract An advisory panel of the U.S. Food and Drug Administration unanimously recommended approval of Roche's Cobas human papillomavirus DNA test for use as a primary cervical cancer screening tool for women ages 25 and older. If approved, it could be used in lieu of traditional Pap testing.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
